In this video, I share a story about a chance encounter at my granddaughter’s track meet that led to a fascinating conversation about a groundbreaking treatment for C. difficile infection (CDI or C Diff) I met a British expat and nurse who moved to Winnipeg four years ago. While discussing the challenges of transferring her 26 years of nursing experience to Canada, we discovered an amazing coincidence: she used to work on a C. Diff ward in the UK, and I’m involved in developing a potential game-changer for the very same infection. What is C. Difficile? C. diff is a serious bacterial infection that often affects people in hospitals, typically after they’ve taken antibiotics for something else. It’s difficult to treat, costly for healthcare systems, and until now, there have been no effective ways to prevent it.
The Innovation: MEGGA MIX We’ve developed a novel treatment called MEGGA MIX (MEGGAMIX.com) . Oral antibodies in whole egg powder mixed with milk and showing incredible results.
• Treatment: in clinical trials it’s working better than the present standard of care antibiotics that also often see recurrent infections.
• Prevention: Most excitingly, it has the potential to be the first preventive treatment for C. diff, something major pharmaceutical companies like Sanofi and Pfizer have failed to achieve with vaccines.
The nurse immediately understood the massive implications, especially for government-run healthcare systems like the UK’s NHS or Medicare in the US, where a single hospital-acquired C. diff case can cost an extra $25,000-$30,000 to treat. The biggest challenge? We’re developing this in Winnipeg, which isn’t exactly known as a biopharma hub, and we’re working with a type of treatment the industry isn’t familiar with yet. But the results speak for themselves. Want to learn more?
Check out the websites: 🔗 https://meggabiotics.com/ 🔗 https://meggamix.com/
Thanks for watching!
#cdiff #cdifficile #medicalbreakthrough #canadianinnovation #winnipeg #healthcare #microbiome #antibodies #clinicaltrial
